image by: HWN

HWN Suggests

Does hormone replacement therapy increase my risk of breast cancer?

Some studies show using HRT with estrogen and progesterone for more than 10 years might put you at increased risk for breast cancer. It’s best to take HRT only for as long as it’s needed or until menopausal symptoms finish. For women and people assigned female at birth, estrogen therapy alone can increase your risk of endometrial cancer. However, estrogen coupled with progestogen (also known as progestin) lowers this risk. Providers will likely prescribe them hand in hand. Regardless of whether you use HRT, it’s important to stay up to date on routine cancer screenings like annual mammograms to prevent breast cancer or detect it early, when treatment is more likely to be successful.

read full article

Featured

 Hormone Replacement Therapy (HRT) and Breast Cancer Risk: What the Latest Research Reveals

For example, a more nuanced explanation is now available that further clarifies the relationship between HRT and breast cancer risk, as conclusions drawn from study data in 2002 were based largely on women older than 60. Findings from the 20-year follow-up to the WHI study found that breast cancer risk increased with longer use of combination HRT, but absolute risk (the chance something will happen) was low compared to placebo, and women aged 50 to 59 had lower risk than women aged 60 and older. Estrogen-only HRT lowered breast cancer risk in women with prior hysterectomies in all age groups studied.

 The FDA Will Strip the Misleading Safety Warning From Hormone Therapy. Here’s What This Means for You

The “black box” label is long outdated—and doing away with it opens up room for more nuanced conversations.

Articles of Interest

Does HRT Really Cause Breast Cancer?

Confused about the link between HRT and breast cancer? ???? Let's cut through the myths and explore what research really says. Join me in debunking misinformation with evidence-based insights!

Breast cancer risk in younger women may be influenced by hormone therapy

Scientists at the National Institutes of Health (NIH) have found that two common types of hormone therapy may alter breast cancer risk in women before age 55. Researchers discovered that women treated with unopposed estrogen hormone therapy (E-HT) were less likely to develop the disease than those who did not use hormone therapy. They also found that women treated with estrogen plus progestin hormone therapy (EP-HT) were more likely to develop breast cancer than women who did not use hormone therapy. Together, these results could help to guide clinical recommendations for hormone therapy use among younger women.

Does hormone replacement therapy (HRT) increase the risk of cancer?

Does combined HRT increase the risk of cancer? Breast cancer: combined HRT slightly increases the risk of breast cancer. This increased risk gets bigger the longer HRT is used. When HRT is stopped, the increased risk goes down over time. This takes longer, the longer that HRT was used. Combined HRT affects breast cancer risk more than oestrogen-only HRT.

Does hormone replacement therapy (HRT) increase the risk of cancer?

HRT slightly increases the risk of some cancers, but the risk is small. For most people, the benefits will outweigh the risks. Find out what HRT is, and how different types of HRT impact cancer risk.

Does HRT (Hormone Replacement Therapy) Increase Breast Cancer Risk?

In women with no history of breast cancer who are over the age of 50, combination HRT taken for five or more years slightly increases breast cancer risk, according to Women’s Health Initiative studies and other research. Whether this risk applies to all women with no history of breast cancer over the age of 50, or whether there are some groups that might not have any increased risk at all, is controversial. Many experts agree, though, that any increase in risk is likely to be small.

Hormone Therapy and Risk of Breast Cancer: Where Are We Now?

The combined results from the aforesaid HRT trials are varied, and thus, confound an unequivocal approach to treating menopausal symptoms. Conversely, when endeavoring to assess the risks associated with HRT, we recognize the disadvantages of untreated vasomotor symptoms, which can impair quality of life and diminish work productivity [36]. Perhaps, before initiating HRT, the physician and patient should thoughtfully engage in discourse that incorporates the individual’s clinical symptoms and attendant risk profile.

the NNT

The topic is complex and difficult to study even in randomized trials, and an individual"s baseline risk of cancer (due to genetics, lifestyle, etc.) are clearly much more important determinants than any pill. Therefore the numbers reported here and from any other study on the topic, should be tailored whenever possible to an individual"s baseline risk. This would offer a more individualized estimate of true risk.